Radiation-enhanced therapeutic targeting of galectin-1 enriched malignant stroma in triple negative breast cancer

Keyphrases

• Therapeutic Targeting 100%
• Triple-negative Breast Cancer 100%
• Galectin-1 (Gal-1) 100%
• Tumor Model 16%
• Tumor Cells 16%
• Chemotherapy 16%
• Clinically Significant 16%
• Endothelial Cells 16%
• Fibroblasts 16%
• Therapeutic Approaches 16%
• Treatment Regimen 16%
• Radiation Dose 16%
• Targeted Therapy 16%
• FDA-approved Drugs 16%
• Tumor Metastasis 16%
• Clinical Samples 16%
• Radiation Effects 16%
• Tumor Targeting 16%
• Endothelium 16%
• Cisplatin 16%
• Receptor-mediated 16%
• Ongoing Clinical Trials 16%
• Targeted Liposomes 16%
• Targeted Delivery 16%
• Arsenic 16%
• Combinational Therapy 16%
• Tumor-associated 16%
• Breast Tumor Microenvironment 16%
• Tumor Inhibition 16%
• Enhanced Delivery 16%
• Combined Treatment 16%
• Epithelial Cancer Cells 16%
• Breast Cancer Model 16%
• Orthotopic Tumor 16%
• Murine Tumor Model 16%
• Nanotherapeutic Strategies 16%
• Anginex 16%
• 3D Tumor 16%
• Tumor Tissue Analog 16%
• Loaded Liposomes 16%
• Cytotoxic Payload 16%
• Stromal Targeting 16%

Medicine and Dentistry

• Stroma 100%
• Triple Negative Breast Cancer 100%
• Galectin 1 100%
• Neoplasm 66%
• Tumor Model 33%
• Liposome 33%
• Receptor 16%
• Tumor Progression 16%
• Metastatic Carcinoma 16%
• Tumor Cell 16%
• Endothelial Cell 16%
• Cancer Cell 16%
• Cancer Model 16%
• Anginex 16%
• Clinical Trial 16%
• Targeted Therapy 16%
• Cisplatin 16%
• Fibroblast 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Triple Negative Breast Cancer 100%
• Galectin 1 100%
• Neoplasm 83%
• Tumor Model 33%
• Liposome 33%
• Cisplatin 16%
• Chemotherapy 16%
• Anginex 16%
• Clinical Trial 16%
• Tumor Growth 16%
• Malignant Neoplasm 16%
• Receptor 16%
• Cancer Model 16%